Clovis Oncology Inc. (CLVS) Sees Strong Trading Volume
Shares of Clovis Oncology Inc. (NASDAQ:CLVS) saw unusually-strong trading volume on Wednesday . Approximately 3,186,684 shares were traded during mid-day trading, an increase of 5% from the previous session’s volume of 3,032,915 shares.The stock last traded at $24.60 and had previously closed at $24.22.
Several analysts have commented on CLVS shares. WallachBeth Capital lowered their price objective on shares of Clovis Oncology from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Monday, May 9th. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $14.00 price objective on shares of Clovis Oncology in a research report on Thursday, August 25th. Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. SunTrust Banks Inc. lifted their price objective on shares of Clovis Oncology from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, August 24th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Clovis Oncology in a research report on Thursday, June 30th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $30.48.
The company’s 50-day moving average is $17.01 and its 200 day moving average is $16.34. The stock’s market capitalization is $953.67 million.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the company earned ($2.10) EPS. Equities analysts forecast that Clovis Oncology Inc. will post ($9.33) EPS for the current year.
A hedge fund recently bought a new stake in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned 0.09% of Clovis Oncology at the end of the most recent reporting period.
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.